Saroglitazar

The US and domestic formulation businesses help the pharma company to do well in Q3

Cadila: More a COVID hedge in the near term

Cadila's India presence -- at about 45 per cent of sales -- is similar in size as the US business and provides better cash-flow visibility

Ideas For Profit | Cadila: COVID opportunity, complex pharma pipeline offer strong risk reward

Cadila’s stock was primed by a series of potential roll outs to meet the COVID-19 challenge. Beyond COVID, the company is steadily building up its injectable and biosimilars portfolio - the areas to look at for the longer term.

Zydus Cadila eyes big bucks in fatty liver disease treatment

Drug-maker Zydus Cadila may soon enter and corner a large chunk of a multi-billion dollar drug opportunity in the treatment of fatty liver disease.

Cadila up 2% on USFDA nod for clinical trials of diabetes drug

"The US Food & Drug Administration has approved company's plan to initiate a phase 2 clinical trials of Saroglitazar (Lipaglyn) in patients with non-alcoholic steatohepatitis (NASH) of the liver in USA," the Ahmedabad-based pharma company says in its filing.

Zydus gets FDA nod for phase II clinical trial of Saroglitazar

Drug firm Zydus Cadila on June 4 said it has received approval from the US health regulator to initiate a phase II clinical trial of Saroglitazar in patients with non-alcoholic steatohepatitis (NASH) of the liver